ConductScience.org, home

Paper12475151

Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.

Su WJ and 1 other. Int J Tuberc Lung Dis, 2002. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Papers, record 12475151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12475151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
PubMed
Journal
Int J Tuberc Lung Dis
PubMed
Year
2002
PubMed
Publication types
Clinical Trial, Comparative Study, Evaluation Study, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
0.92
iCite
Revised in PubMed
2019-12-10
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Su WJW J
2Perng RPR P

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
IsoniazidMajor topic
Mycobacterium tuberculosisMajor topic
PyrazinamideMajor topic
RifampinMajor topic
Tuberculosis, PulmonaryMajor topic
Adult
Drug Combinations
Female
Humans
Male
Patient Compliance
Sputum
Taiwan

Source PubMed

Download CSV of topics

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
38500521Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes.J Health Econ Outcomes Res2024https://conductscience.org/library/papers/38500521PubMed
32476718Health technology assessment of fixed-dose combination regimen in treatment of newly diagnosed smear-positive pulmonary tuberculosis: A meta-analysis.Med J Armed Forces India2020https://conductscience.org/library/papers/32476718PubMed
30089476
Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar.
BMC Infect Dis2018https://conductscience.org/library/papers/30089476PubMed
28063922Efficacy and safety of a four-drug fixed-dose combination regimen versus separate drugs for treatment of pulmonary tuberculosis: a systematic review and meta-analysis.Braz J Microbiol2017https://conductscience.org/library/papers/28063922PubMed
27322164Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.PLoS One2016https://conductscience.org/library/papers/27322164PubMed
27186634Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.Cochrane Database Syst Rev2016https://conductscience.org/library/papers/27186634PubMed
26106962Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.Clinics (Sao Paulo)2015https://conductscience.org/library/papers/26106962PubMed
26056374Intermittent Versus Daily Pulmonary Tuberculosis Treatment Regimens: A Meta-Analysis.Clin Med Res2015https://conductscience.org/library/papers/26056374PubMed
25879615Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study.BMC Infect Dis2015https://conductscience.org/library/papers/25879615PubMed
25276422The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis.AIDS Res Treat2014https://conductscience.org/library/papers/25276422PubMed
19753109Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.PLoS Med2009https://conductscience.org/library/papers/19753109PubMed
19475775Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.Vasc Health Risk Manag2009https://conductscience.org/library/papers/19475775PubMed
17519122Compliance and fixed-dose combination therapy.Curr Hypertens Rep2007https://conductscience.org/library/papers/17519122PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12475151

GET https://conductscience.org/api/papers/v1/12475151/authors